The Latin America, Middle East and Africa Gabapentin Market would witness market growth of 7.6% CAGR during the forecast period (2022-2028).
The market's growth is further fueled by awareness efforts like National Epilepsy Awareness Month in November, which work to increase understanding of the condition and encourage proactive measures to help control it. Also, more doctors nowadays are prescribing gabapentin rather than opioids to significantly reduce drug addiction. As a result, this is expected to increase the demand for medicine. The rising demand for gabapentin as a painkiller, particularly for neuropathic pain, is one of the main factors driving the market.
In addition, the increasing prevalence of chronic pain diseases like spinal cord injuries, shingles, and diabetic neuropathy, which are challenging to treat with traditional medicines, also increases the demand for gabapentin drugs. Therefore, many doctors are now prescribing gabapentin "off-label" for both chronic and acute pain, even though the medication was initially created and used to treat epilepsy and seizures. Many doctors recommend it in place of opioids, and some recommend it in addition to opioids.
Premised on the Global Burden of Disease (GBD) Study results, it has been shown that non-communicable diseases (NCD) are emerging as the primary factor in causing death and disability in the Arab region. Years of life lost to early mortality and years spent with a disability are measured using disability-adjusted life years (DALYs), a useful tool for quantifying and ranking disease burden. Neurological illnesses constitute up to 3% of worldwide DALYs, and one-fourth of this category comprises epilepsy. Additionally, among the various causes of DALY, epilepsy was ranked at the 31st position in the region of North Africa and the Middle East. Therefore, the rising incidences of epilepsy and chronic pain in the region are the main factors accelerating the expansion of the gabapentin market in the region.
The Brazil market dominated the LAMEA Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $44.2 million by 2028. The Argentina market is experiencing a CAGR of 8.1% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 7.3% during (2022 - 2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Gabapentin Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
By Application
By Dosage Form
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 